Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited ( (AU:MSB) ) has shared an announcement.
Mesoblast Limited announced the issuance of 3,225,000 fully paid ordinary shares to institutional and sophisticated investors through a private placement. The company has complied with relevant provisions of the Corporations Act and is not aware of any excluded information, potentially enhancing its financial position and market presence.
More about Mesoblast Limited
Mesoblast Limited is a company operating in the biotechnology industry, focusing on developing regenerative medicine products. They are primarily involved with the development of innovative cellular medicines targeting inflammatory diseases, cardiovascular diseases, and back pain.
YTD Price Performance: -9.09%
Average Trading Volume: 123,813
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.27B
See more insights into MSB stock on TipRanks’ Stock Analysis page.
